Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
Juan González-MorenoManuel Raya-CruzInés LosadaAna Paula CachedaCristina OliverBartomeu ColomPublished in: Rheumatology international (2018)
Anti-MDA5 antibodies have been strongly associated with rapidly progressive interstitial lung disease (RP-ILD) in dermatomyositis (DM) patients, especially in the clinically amyopathic subset (CADM). We present a case of anti-MDA5 antibody-associated RP-ILD in a patient with arthritis but with no other clinical signs suggestive of DM or CADM successfully treated with a combination of cyclophosphamide, cyclosporine and corticoids. A review of the literature was also done. Despite its rarity, anti-MDA5 antibody-associated ILD should be suspected in cases of RP-ILD even without other signs of DM or CADM as prompt and aggressive treatment could improve prognosis.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- breast cancer cells
- multiple sclerosis
- cell cycle arrest
- ejection fraction
- low dose
- high dose
- type diabetes
- cell proliferation
- case report
- cell death
- insulin resistance
- smoking cessation
- skeletal muscle
- combination therapy
- replacement therapy
- pi k akt
- wound healing